Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTP42:KVA4 PK and Bioavailability Study in Healthy Volunteers
NCT06092788Phase 1Completed
- Sponsor
- ATXA Therapeutics
- Start
- Nov 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NTP42 in pulmonary arterial hypertension (PAH) (2 arms), sponsored by ATXA Therapeutics. Primary endpoints: Safety and tolerability of NTP42:KVA4, Pharmacokinetics of NTP42:KVA4 Capsule at 48 hours and 1 more. Started Nov 2023; status: completed.
02
Drugs
NTP42
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06092788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092788.